New drug MGC028 enters first human tests for tough cancers
NCT ID NCT06723236
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colon cancers) that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or stop them from growing. Participants receive the drug every 3 weeks and are closely monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber/Harvard Cancer Center
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
-
Icahn School of Medicine at Mt. Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
-
Mass General Brigham
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
South Texas Accelerated Research Therapeutics (START) Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact
-
South Texas Accelerated Research Therapeutics (START) San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
UCSF - Helen Diller Family Cancer Center
RECRUITINGSan Francisco, California, 94115, United States
Contact
Conditions
Explore the condition pages connected to this study.